Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Allan

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Comprehensive Therapy|April 1, 1978
The precipitins and hypersensitivity reactions in cystic fibrosisH McFarlene, J D Allan, A Malhotra, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1985
Comparative in vitro activities of cefpiramide and apalcillin individually and in combinationJ D Allan, G M Eliopoulos, M J Ferraro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1986
Human T-lymphotropic virus type III infection in previously immunocompromised hostsJ E Groopman, S M Hammer, S E Sallan, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|January 1, 1990
Typhoidal tularemiaD M Marcus, A R Frederick, T Hodges, et al.
European Urology|August 31, 2001
Laparoscopic radical nephrectomyJ D Allan, D A Tolley, J H Kaouk, et al.
AIDS Research and Human Retroviruses|January 1, 1987
Characterization of serum neutralization response to the human immunodeficiency virus (HIV)J E Groopman, P M Benz, R Ferriani, et al.
British Medical Journal|February 22, 1975
Immune complexes in cystic fibrosisH McFarlane, A Holzel, P Brenchley, et al.
The Science of the Total Environment|October 27, 2004
Street canyon aerosol pollutant transport measurementsI D Longley, M W Gallagher, J R Dorsey, et al.
Clinical Immunology and Immunopathology|January 1, 1991
Characterization of autoantibodies to the CD4 molecule in human immunodeficiency virus infectionI Sekigawa, J E Groopmen, J D Allan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 1993
Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudineJ D Allan, K J Connolly, H Fitch, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Comprehensive Therapy|April 1, 1978
The precipitins and hypersensitivity reactions in cystic fibrosisH McFarlene, J D Allan, A Malhotra, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1985
Comparative in vitro activities of cefpiramide and apalcillin individually and in combinationJ D Allan, G M Eliopoulos, M J Ferraro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1986
Human T-lymphotropic virus type III infection in previously immunocompromised hostsJ E Groopman, S M Hammer, S E Sallan, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|January 1, 1990
Typhoidal tularemiaD M Marcus, A R Frederick, T Hodges, et al.
European Urology|August 31, 2001
Laparoscopic radical nephrectomyJ D Allan, D A Tolley, J H Kaouk, et al.
AIDS Research and Human Retroviruses|January 1, 1987
Characterization of serum neutralization response to the human immunodeficiency virus (HIV)J E Groopman, P M Benz, R Ferriani, et al.
British Medical Journal|February 22, 1975
Immune complexes in cystic fibrosisH McFarlane, A Holzel, P Brenchley, et al.
The Science of the Total Environment|October 27, 2004
Street canyon aerosol pollutant transport measurementsI D Longley, M W Gallagher, J R Dorsey, et al.
Clinical Immunology and Immunopathology|January 1, 1991
Characterization of autoantibodies to the CD4 molecule in human immunodeficiency virus infectionI Sekigawa, J E Groopmen, J D Allan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 1993
Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudineJ D Allan, K J Connolly, H Fitch, et al.
Pageof 7